The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

The Centers for Disease Control and Prevention says children without underlying health conditions "may receive" a COVID-19 ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA’s approval was based on a study of 11,400 people ages 12 and older that compared the new low-dose vaccine with ...

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 ...